{"doi":"10.1002/alz.70367","title":"Structural and functional connectivity in tau mutation carriers: from presymptomatic to symptomatic frontotemporal dementia","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION</jats:title>\n                    <jats:p>\n                      Microtubule‐associated protein tau (\n                      <jats:italic>MAPT</jats:italic>\n                      ) mutations cause frontotemporal dementia (FTD), characterised by behavioural, language, and motor impairments due to brain connectivity disruptions. We investigated structural and functional connectivity in 86 mutation carriers and 272 controls to map connectivity changes at different disease stages.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS</jats:title>\n                    <jats:p>The CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center (NACC) Behaviour and Language domains (CDR plus NACC FTLD) stratified carriers into three groups: asymptomatic, prodromal, and symptomatic. We extracted measures of cortical thickness, white matter integrity, and functional connectivity, which were compared between each carrier group and controls using linear mixed models.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>Early isolated functional disruptions in salience/visual networks were present in asymptomatic carriers, along with anterior cingulate gray matter reductions. In prodromal carriers, functional changes extended to other networks, with additional structural damage in temporal poles/cingulate.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION</jats:title>\n                    <jats:p>\n                      This study shows that functional networks likely drive lifelong compensation for a genetically determined disease, manifesting clinically when structural damage reaches a critical threshold. This supports connectivity measures as potential biomarkers for\n                      <jats:italic>MAPT</jats:italic>\n                      ‐related neurodegeneration.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights</jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Our findings reveal the progressive and staged nature of structural and functional connectivity alterations in\n                            <jats:italic>MAPT</jats:italic>\n                            mutation carriers, with distinct patterns at each disease stage.\n                          </jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In asymptomatic carriers, we identified early functional connectivity alterations in salience and visual networks, despite preserved white matter and only subtle gray matter atrophy. These appear to represent both response to pathology and possible compensatory mechanisms.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In prodromal carriers, functional connectivity alterations were accompanied by structural damage, including cortical atrophy and white matter tract disruptions, in regions directly connected to early‐affected networks.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The sequential progression, from functional connectivity changes to structural degeneration, aligns with the hypothesis that tau propagates along axonal connections, disrupting neural network integrity before measurable atrophy occurs.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We propose a theoretical data‐driven model of biomarker evolution in\n                            <jats:italic>MAPT</jats:italic>\n                            mutation carriers, highlighting functional disruptions as early indicators and structural damage as a later‐stage hallmark.\n                          </jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>These connectivity biomarkers have the potential to inform therapeutic strategies and clinical trial design.</jats:p>\n                        </jats:list-item>\n                      </jats:list>\n                    </jats:p>\n                  </jats:sec>","journal":"Alzheimer's &amp; Dementia","year":2025,"id":639812,"datarank":0.31856633155770947,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.026679809199412416,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.026679809199412416,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":5,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1662625,"name":"Vincent Le Du","orcid":null,"position":1,"is_corresponding":false},{"id":1320159,"name":"Matthieu Joulot","orcid":"0009-0006-2115-3876","position":2,"is_corresponding":false},{"id":1662626,"name":"Ninon Peysson","orcid":null,"position":3,"is_corresponding":false},{"id":295711,"name":"Marion Houot","orcid":"0000-0002-3684-1763","position":4,"is_corresponding":false},{"id":777512,"name":"Benoît Béranger","orcid":"0000-0003-0704-9854","position":5,"is_corresponding":false},{"id":635058,"name":"Lucy L. Russell","orcid":"0000-0001-5023-5893","position":6,"is_corresponding":false},{"id":1387996,"name":"Phoebe H. Foster","orcid":"0000-0001-6300-6598","position":7,"is_corresponding":false},{"id":1387997,"name":"Eve Ferry‐Bolder","orcid":"0009-0006-5083-0901","position":8,"is_corresponding":false},{"id":233804,"name":"John C. van Swieten","orcid":"0000-0001-6278-6844","position":9,"is_corresponding":false},{"id":1662627,"name":"Lize Jiskoot","orcid":null,"position":10,"is_corresponding":false},{"id":233781,"name":"Harro Seelaar","orcid":"0000-0003-1989-7527","position":11,"is_corresponding":false},{"id":1644693,"name":"Raquel Sanchez‐Valle","orcid":null,"position":12,"is_corresponding":false},{"id":233776,"name":"Robert Laforce","orcid":"0000-0002-2031-490X","position":13,"is_corresponding":false},{"id":65581,"name":"Caroline Graff","orcid":"0000-0002-9949-2951","position":14,"is_corresponding":false},{"id":95064,"name":"Daniela Galimberti","orcid":"0000-0002-9284-5953","position":15,"is_corresponding":false},{"id":65635,"name":"Rik Vandenberghe","orcid":"0000-0001-6237-2502","position":16,"is_corresponding":false},{"id":588061,"name":"Alexandre de Mendonça","orcid":"0000-0002-0488-1453","position":17,"is_corresponding":false},{"id":108612,"name":"Pietro Tiraboschi","orcid":"0000-0002-2171-1720","position":18,"is_corresponding":false},{"id":461716,"name":"Isabel Santana","orcid":"0000-0002-8114-9434","position":19,"is_corresponding":false},{"id":271295,"name":"Alexander Gerhard","orcid":"0000-0002-8071-6062","position":20,"is_corresponding":false},{"id":84330,"name":"Johannes Levin","orcid":"0000-0001-5092-4306","position":21,"is_corresponding":false},{"id":142646,"name":"Sandro Sorbi","orcid":null,"position":22,"is_corresponding":false},{"id":635053,"name":"Markus Otto","orcid":"0000-0003-4273-4267","position":23,"is_corresponding":false},{"id":652160,"name":"Maxime Bertoux","orcid":"0000-0002-5283-503X","position":24,"is_corresponding":false},{"id":652174,"name":"Thibaud Lebouvier","orcid":"0000-0002-4386-6045","position":25,"is_corresponding":false},{"id":233774,"name":"Simon Ducharme","orcid":"0000-0002-7309-1113","position":26,"is_corresponding":false},{"id":1662628,"name":"Chris R. Butler","orcid":null,"position":27,"is_corresponding":false},{"id":65598,"name":"Isabelle Le Ber","orcid":"0000-0002-2508-5181","position":28,"is_corresponding":false},{"id":635052,"name":"Elizabeth Finger","orcid":"0000-0003-4461-7427","position":29,"is_corresponding":false},{"id":253935,"name":"Maria Carmela Tartaglia","orcid":"0000-0002-5944-8497","position":30,"is_corresponding":false},{"id":108607,"name":"Mario Masellis","orcid":"0000-0002-6244-2096","position":31,"is_corresponding":false},{"id":271283,"name":"James B. Rowe","orcid":"0000-0001-7216-8679","position":32,"is_corresponding":false},{"id":65630,"name":"Matthis Synofzik","orcid":"0000-0002-2280-7273","position":33,"is_corresponding":false},{"id":1567468,"name":"Fermin Moreno","orcid":null,"position":34,"is_corresponding":false},{"id":65560,"name":"Barbara Borroni","orcid":"0000-0001-9340-9814","position":35,"is_corresponding":false},{"id":65617,"name":"Jonathan D. Rohrer","orcid":"0000-0002-6155-8417","position":36,"is_corresponding":false},{"id":933970,"name":"Raffaella Migliaccio","orcid":"0000-0002-6960-8474","position":37,"is_corresponding":false},{"id":846073,"name":"Arabella Bouzigues","orcid":"0000-0002-0267-8590","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Structural and functional connectivity in tau mutation carriers: from presymptomatic to symptomatic frontotemporal dementia","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION</jats:title>\n                    <jats:p>\n                      Microtubule‐associated protein tau (\n                      <jats:italic>MAPT</jats:italic>\n                      ) mutations cause frontotemporal dementia (FTD), characterised by behavioural, language, and motor impairments due to brain connectivity disruptions. We investigated structural and functional connectivity in 86 mutation carriers and 272 controls to map connectivity changes at different disease stages.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS</jats:title>\n                    <jats:p>The CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center (NACC) Behaviour and Language domains (CDR plus NACC FTLD) stratified carriers into three groups: asymptomatic, prodromal, and symptomatic. We extracted measures of cortical thickness, white matter integrity, and functional connectivity, which were compared between each carrier group and controls using linear mixed models.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>Early isolated functional disruptions in salience/visual networks were present in asymptomatic carriers, along with anterior cingulate gray matter reductions. In prodromal carriers, functional changes extended to other networks, with additional structural damage in temporal poles/cingulate.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION</jats:title>\n                    <jats:p>\n                      This study shows that functional networks likely drive lifelong compensation for a genetically determined disease, manifesting clinically when structural damage reaches a critical threshold. This supports connectivity measures as potential biomarkers for\n                      <jats:italic>MAPT</jats:italic>\n                      ‐related neurodegeneration.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights</jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Our findings reveal the progressive and staged nature of structural and functional connectivity alterations in\n                            <jats:italic>MAPT</jats:italic>\n                            mutation carriers, with distinct patterns at each disease stage.\n                          </jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In asymptomatic carriers, we identified early functional connectivity alterations in salience and visual networks, despite preserved white matter and only subtle gray matter atrophy. These appear to represent both response to pathology and possible compensatory mechanisms.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In prodromal carriers, functional connectivity alterations were accompanied by structural damage, including cortical atrophy and white matter tract disruptions, in regions directly connected to early‐affected networks.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The sequential progression, from functional connectivity changes to structural degeneration, aligns with the hypothesis that tau propagates along axonal connections, disrupting neural network integrity before measurable atrophy occurs.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We propose a theoretical data‐driven model of biomarker evolution in\n                            <jats:italic>MAPT</jats:italic>\n                            mutation carriers, highlighting functional disruptions as early indicators and structural damage as a later‐stage hallmark.\n                          </jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>These connectivity biomarkers have the potential to inform therapeutic strategies and clinical trial design.</jats:p>\n                        </jats:list-item>\n                      </jats:list>\n                    </jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40673371","pmcid":"PMC12268314","openalex_id":"https://openalex.org/W4412489184","authors":[],"funders":[{"funder_name":"Stichting Dioraphte","grant_id":"09‐02‐03‐00","title":null},{"funder_name":"Vetenskapsrådet","grant_id":"2018‐02754","title":null},{"funder_name":"Wellcome Trust","grant_id":"103838","title":"Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease."},{"funder_name":"Wellcome Trust","grant_id":"220258","title":"Bridging the gap: biophysical models of human frontotemporal lobar degeneration"},{"funder_name":"Medical Research Council","grant_id":"MC_UU_00030/14","title":"Decision making and dementia: from mechanisms to clinical trials"},{"funder_name":"Medical Research Council","grant_id":"MR/T033371/1","title":"MICA: Dementias Platform UK 2 - Integrated Dementia Experimental Medicine"},{"funder_name":"Instituto de Salud Carlos III","grant_id":"PI19/01637","title":null},{"funder_name":"Dioraphte Foundation","grant_id":"09-02-03-00","title":null},{"funder_name":"ZonMw","grant_id":"10510032120002","title":null},{"funder_name":"Alzheimer's Research UK Clinical Research","grant_id":"ARUK-CRF2017B-2","title":null},{"funder_name":"Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology","grant_id":"EXC 2145 SyNergy-ID 390857198","title":null},{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"NIHR203312","title":null},{"funder_name":"European Reference Network for Rare Neurological Diseases (ERN-RND)","grant_id":"No. 739510","title":null},{"funder_name":"Association for Frontotemporal Dementias Research","grant_id":"2009","title":null},{"funder_name":"Vetenskapsrådet","grant_id":"2018-02754","title":null},{"funder_name":"Neurodegenerative Disease Research-Prefrontals Vetenskapsrådet Dnr","grant_id":"529-2014-7504","title":null},{"funder_name":"Deltaplan Dementie","grant_id":"733 051 042","title":null},{"funder_name":"Neurodegenerative Disease Research GENFI-PROX","grant_id":"2019-02248","title":null},{"funder_name":"Dutch Research Council (NWO)","grant_id":"HCMI 056-13-018","title":null},{"funder_name":"Fundació Marató de TV3","grant_id":"20143810","title":null},{"funder_name":"MRC Clinician Scientist Fellowship","grant_id":"MR/M008525/1","title":"Developing an evidence base for trials in genetic frontotemporal dementia - measures of disease onset and progression"},{"funder_name":"Canadian Institute of Health Research","grant_id":"327387","title":null},{"funder_name":"Canadian Institutes of Health Research","grant_id":"unidentified","title":"unidentified"},{"funder_name":"UK Research and Innovation","grant_id":"MR/M023664/1","title":"The UK GENetic Frontotemporal dementia Initiative (UK GENFI)"},{"funder_name":"Netherlands Organisation for Scientific Research (NWO)","grant_id":"056-13-018","title":"Functional MRI as a biomarker in the presymptomatic and early stage of FTD"},{"funder_name":"Alzheimer Nederland","grant_id":"","title":null},{"funder_name":"Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone","grant_id":"","title":null},{"funder_name":"Research into Frontotemporal Dementia","grant_id":"","title":null},{"funder_name":"Wellcome Trust","grant_id":"","title":null},{"funder_name":"Alzheimer Foundation","grant_id":"","title":null},{"funder_name":"Germany's Federal Ministry of Education and Research (BMBF)","grant_id":"","title":null},{"funder_name":"Mady Browaeys","grant_id":"","title":null},{"funder_name":"Tau Consortium","grant_id":"","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft German Research Foundation","grant_id":"","title":null},{"funder_name":"Fondation Philippe Chatrier","grant_id":"","title":null},{"funder_name":"France Alzheimer","grant_id":"","title":null},{"funder_name":"UCLH Biomedical Research Centre","grant_id":"","title":null},{"funder_name":"Dementia Foundation","grant_id":"","title":null},{"funder_name":"University College London Hospitals Biomedical Research Centre","grant_id":"","title":null},{"funder_name":"Bluefield Project","grant_id":"","title":null},{"funder_name":"Brain Foundation","grant_id":"","title":null},{"funder_name":"Cambridge University Centre for Frontotemporal Dementia","grant_id":"","title":null},{"funder_name":"Miriam Marks Brain Research UK","grant_id":"","title":null},{"funder_name":"FTD Inititative-Schörling Foundation","grant_id":"","title":null},{"funder_name":"Fondation Recherche Alzheimer","grant_id":"","title":null},{"funder_name":"National Institute for Health and Care Research","grant_id":"","title":null},{"funder_name":"Weston Brain Institute and Ontario Brain Institute","grant_id":"","title":null},{"funder_name":"Fondation Vaincre Alzheimer","grant_id":"","title":null},{"funder_name":"Region Stockholm ALF-project","grant_id":"","title":null},{"funder_name":"Canadian Institute of Health Research operating","grant_id":"","title":null},{"funder_name":"Neurodegenerative Disease Research-GENFI-PROX","grant_id":"","title":null},{"funder_name":"Rosita Gomez association","grant_id":"","title":null},{"funder_name":"Germany's Federal Ministry of Education and Research (BMBF)","grant_id":"","title":null},{"funder_name":"Miriam Marks Brain Research UK","grant_id":"","title":null},{"funder_name":"Rosita Gomez association","grant_id":"","title":null},{"funder_name":"Neurodegenerative Disease Research-GENFI-PROX","grant_id":"","title":null},{"funder_name":"Dementia Foundation","grant_id":"","title":null},{"funder_name":"Fondation Recherche Alzheimer","grant_id":"","title":null},{"funder_name":"Fondation Vaincre Alzheimer","grant_id":"","title":null},{"funder_name":"Fondation Philippe Chatrier","grant_id":"","title":null},{"funder_name":"France Alzheimer","grant_id":"","title":null},{"funder_name":"University College London Hospitals Biomedical Research Centre","grant_id":"","title":null},{"funder_name":"Deutsche Forschungsgemeinschaft German Research Foundation","grant_id":"","title":null},{"funder_name":"Alzheimer Nederland","grant_id":"","title":null},{"funder_name":"Region Stockholm ALF-project","grant_id":"","title":null},{"funder_name":"Alzheimer Foundation","grant_id":"","title":null},{"funder_name":"Tau Consortium","grant_id":"","title":null},{"funder_name":"Research into Frontotemporal Dementia","grant_id":"","title":null},{"funder_name":"Weston Brain Institute and Ontario Brain Institute","grant_id":"","title":null},{"funder_name":"Bluefield Project","grant_id":"","title":null},{"funder_name":"Mady Browaeys","grant_id":"","title":null},{"funder_name":"Cambridge University Centre for Frontotemporal Dementia","grant_id":"","title":null},{"funder_name":"FTD Inititative-Schörling Foundation","grant_id":"","title":null},{"funder_name":"Canadian Institute of Health Research operating","grant_id":"","title":null},{"funder_name":"Brain Foundation","grant_id":"","title":null},{"funder_name":"National Institute for Health and Care Research","grant_id":"","title":null},{"funder_name":"Wellcome Trust","grant_id":"","title":null},{"funder_name":"Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone","grant_id":"","title":null}],"total_grants":78,"fwci":4.4022,"citation_percentile":0.94974051,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.70367","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.70367","host_type":"publisher"},{"url":"https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.70367","host_type":"publisher"},{"url":"https://alz-journals.onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.70367","host_type":"publisher"},{"url":"https://doi.org/10.1002/alz.70367","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40673371","host_type":"repository"},{"url":"https://lirias.kuleuven.be/handle/20.500.12942/774333","host_type":"repository"},{"url":"http://nbn-resolving.de/urn:nbn:de:bvb:19-epub-129954-1","host_type":"repository"},{"url":"https://pure.eur.nl/en/publications/d3e6efa9-5b59-494b-8491-24269956f4a8","host_type":"repository"},{"url":"https://lilloa.hal.science/hal-05303219","host_type":"repository"},{"url":"https://hdl.handle.net/2434/1178418","host_type":"repository"},{"url":"https://hdl.handle.net/11379/637643","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12268314","host_type":"repository"},{"url":"https://epub.ub.uni-muenchen.de/129954/1/Alzheimer_s___Dementia_-_2025_-_Bouzigues_-_Structural_and_functional_connectivity_in_tau_mutation_carriers__from.pdf","host_type":"repository"},{"url":"https://pure.eur.nl/ws/files/202289503/Structural_and_functional_connectivity_in_tau_mutation_carriers.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12268314","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12268314?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1002/alz.70367","host_type":""},{"url":"https://pub.dzne.de/record/280021","host_type":""},{"url":"https://ora.ox.ac.uk/objects/uuid:a6b3db49-d453-4195-a4aa-d6492f6789f8","host_type":""},{"url":"https://lilloa.hal.science/hal-05303219v1","host_type":""},{"url":"https://lilloa.hal.science/hal-05303219v1/document","host_type":""},{"url":"https://www.repository.cam.ac.uk/handle/1810/387155","host_type":""},{"url":"https://epub.ub.uni-muenchen.de/129954/","host_type":""}],"fields_of_study":["Amyotrophic Lateral Sclerosis Research","Alzheimer's disease research and treatments","Genetic Neurodegenerative Diseases","0302 clinical medicine","03 medical and health sciences","Humans","Frontotemporal Dementia","tau Proteins","Male","Female","Middle Aged","Mutation","Magnetic Resonance Imaging","Aged","White Matter","Heterozygote","Brain","Prodromal Symptoms"],"mesh_terms":["Aged","Brain","Female","Heterozygote","Humans","Magnetic Resonance Imaging","Male","Middle Aged","Mutation","tau Proteins","Frontotemporal Dementia","Prodromal Symptoms","White Matter"],"keywords":["Frontotemporal dementia","Mutation","Dementia","Functional connectivity","Medicine","Neuroscience","Psychology","Genetics","Internal medicine","Biology","Disease","Gene","Tau","Neurodegeneration","Gray Matter","White Matter","Graph Analysis","Mapt","Tau Pathology","Genetic Frontotemporal Dementia","Macroscale Organization","Male","Frontotemporal Dementia: pathology","MAPT; functional connectivity; genetic frontotemporal dementia; graph analysis; gray matter; macroscale organization; mutation; neurodegeneration; tau; tau pathology; white matter","White Matter: diagnostic imaging","BEHAVIORAL VARIANT","TAUOPATHY","info:eu-repo/classification/ddc/610","tau Proteins: genetics","Brain","Brain: physiopathology","Middle Aged","Magnetic Resonance Imaging","Mutation: genetics","[SDV] Life Sciences [q-bio]","Frontotemporal Dementia: physiopathology","Female","Life Sciences & Biomedicine","Research Article","Heterozygote","Clinical Neurology","Prodromal Symptoms","MAPT protein, human","tau Proteins","NETWORK CONNECTIVITY","ATROPHY","SDG 3 - Good Health and Well-being","THICKNESS","Humans","BRAIN CONNECTIVITY","Brain: diagnostic imaging","Aged","Frontotemporal Dementia: genetics","Science & Technology","functional connectivity; genetic frontotemporal dementia; graph analysis; gray matter; macroscale organization; MAPT; mutation; neurodegeneration; tau; tau pathology; white matter","GENetic Frontotemporal dementia Initiative (GENFI)","DISEASE PROGRESSION","3202 Clinical sciences","1103 Clinical Sciences","Brain: pathology","White Matter: pathology","Geriatrics","5202 Biological psychology","Frontotemporal Dementia: diagnostic imaging","3209 Neurosciences","WHITE-MATTER INTEGRITY","Neurosciences & Neurology","1109 Neurosciences","GENFI"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T02:24:57.598321Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}